Marinus Pharmaceuticals (NASDAQ:MRNS) Raised to Strong-Buy at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) to a strong-buy rating in a research note published on Monday, Zacks.com reports.

A number of other research analysts have also weighed in on the company. Truist Financial reissued a buy rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. HC Wainwright reissued a buy rating and issued a $11.00 price target on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a buy rating to a neutral rating in a research note on Wednesday, August 14th. Oppenheimer raised shares of Marinus Pharmaceuticals from a market perform rating to an outperform rating and set a $6.00 target price on the stock in a research report on Monday, September 23rd. Finally, JMP Securities restated a market outperform rating and issued a $10.00 target price on shares of Marinus Pharmaceuticals in a report on Monday, September 23rd. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of Moderate Buy and a consensus target price of $8.83.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS opened at $1.73 on Monday. The stock has a fifty day moving average price of $1.43 and a 200 day moving average price of $2.41. Marinus Pharmaceuticals has a 1-year low of $1.05 and a 1-year high of $11.26. The company has a debt-to-equity ratio of 5.68, a current ratio of 2.28 and a quick ratio of 2.15. The company has a market cap of $95.04 million, a PE ratio of -0.66 and a beta of 1.13.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The firm had revenue of $8.06 million for the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same period in the prior year, the firm posted ($0.61) earnings per share. Sell-side analysts forecast that Marinus Pharmaceuticals will post -1.88 EPS for the current year.

Institutional Trading of Marinus Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 DIFC Ltd bought a new position in Marinus Pharmaceuticals during the 2nd quarter worth $28,000. SG Americas Securities LLC acquired a new position in shares of Marinus Pharmaceuticals during the second quarter valued at $34,000. AQR Capital Management LLC boosted its holdings in shares of Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 12,934 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Marinus Pharmaceuticals during the second quarter worth about $64,000. Finally, Values First Advisors Inc. increased its holdings in shares of Marinus Pharmaceuticals by 501.8% in the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 52,257 shares during the period. 98.80% of the stock is currently owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.